Paliperidone palmitate is under clinical development by Luye Pharma Group and currently in Pre-Registration for Schizophrenia. According to GlobalData, Pre-Registration drugs for Schizophrenia have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Paliperidone palmitate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Paliperidone palmitate overview

Paliperidone palmitate (LY-03010) is under development for the treatment of schizophrenia and schizoaffective disorders. The drug candidate is an extended-release injectable suspension for single monthly dosage by intramuscular injection. It acts by targeting HTR2A receptor and dopamine D2 receptor.

Luye Pharma Group overview

Luye Pharma Group (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company. It discovers, manufactures and commercializes novel formulations, generic drugs and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its research and development and manufacturing facilities in the US and China and, among others. Luye Pharma is headquartered in Yantai, Shandong, China.

For a complete picture of Paliperidone palmitate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.